Growth signal Barcelona based medical device startup with international visibility and recent leadership appointments indicating active fundraising, expansion, and upcoming commercialization of next generation thrombectomy catheters presents a prime window for strategic partnerships, pilot programs, and distributor agreements in Europe and the US.

Leadership momentum Recent appointment of a new CEO and a new chairman suggests strategic shift toward scalable operations and market entry plans; leverage for engaged discussions on collaboration, co-development, or contract manufacturing and supply partnerships.

Regulatory readiness Award recognition and near-term production ambitions imply progressing regulatory and manufacturing milestones; position quality management, regulatory consulting, and clinical study support as value propositions to accelerate approvals and market access.

Clinical and market potential Commitment to next generation thrombectomy systems for ischemic stroke targets a high-need clinical area with sizeable total addressable market; explore opportunities in hospital deployments, hospital networks, and key opinion leader partnerships for clinical validation and adoption.

Strategic funding Significant funding (~$22M) alongside partnerships and regional awards indicates available capital for partnerships, joint ventures, or contract manufacturing scale; approach for co-development deals, licensing, and manufacturing collaborations to accelerate time-to-market.